NCT02543255View on ClinicalTrials.gov

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

May 27, 2021

Study Completion Date

July 20, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone acetate with prednisone

Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.

DRUG

Leuprolide

Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.

DRUG

Cabazitaxel with peg-filgrastim

Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.

Trial Locations (5)

V5Z 1M9

The Prostate Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 5W9

London Health Sciences Centre, London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

University Health Network, Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) | Biotech Hunter | Biotech Hunter